Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EQ |
---|---|---|
09:32 ET | 1181 | 0.855 |
09:34 ET | 300 | 0.85 |
09:39 ET | 100 | 0.8743 |
09:41 ET | 2591 | 0.85 |
09:45 ET | 100 | 0.89 |
09:54 ET | 2500 | 0.8501 |
09:57 ET | 100 | 0.8748 |
10:01 ET | 100 | 0.86 |
10:14 ET | 1350 | 0.8648 |
10:21 ET | 105 | 0.8603 |
10:24 ET | 100 | 0.8662 |
10:26 ET | 200 | 0.8601 |
10:37 ET | 100 | 0.8601 |
10:42 ET | 100 | 0.8601 |
10:48 ET | 1000 | 0.8641 |
11:00 ET | 100 | 0.8601 |
11:04 ET | 130 | 0.8663 |
11:08 ET | 100 | 0.86 |
11:15 ET | 1200 | 0.8601 |
11:18 ET | 3281 | 0.8601 |
11:20 ET | 100 | 0.8651 |
11:38 ET | 100 | 0.86 |
11:45 ET | 3000 | 0.8686 |
12:07 ET | 200 | 0.86 |
12:14 ET | 100 | 0.8648 |
12:16 ET | 100 | 0.8634 |
12:21 ET | 100 | 0.8601 |
12:23 ET | 100 | 0.86 |
12:50 ET | 1500 | 0.8601 |
12:52 ET | 100 | 0.8601 |
12:54 ET | 1000 | 0.869399 |
12:59 ET | 100 | 0.8601 |
01:14 ET | 1600 | 0.865 |
01:21 ET | 100 | 0.8601 |
01:32 ET | 100 | 0.8601 |
01:35 ET | 100 | 0.8601 |
01:46 ET | 521 | 0.8602 |
01:50 ET | 100 | 0.8601 |
01:55 ET | 100 | 0.8601 |
02:02 ET | 100 | 0.8601 |
02:08 ET | 100 | 0.86949 |
02:09 ET | 1000 | 0.8694 |
02:13 ET | 100 | 0.8601 |
02:15 ET | 100 | 0.8695 |
02:20 ET | 100 | 0.8601 |
02:26 ET | 100 | 0.8601 |
02:29 ET | 100 | 0.8601 |
02:36 ET | 100 | 0.8695 |
02:44 ET | 215 | 0.8695 |
02:47 ET | 100 | 0.8601 |
02:54 ET | 400 | 0.8695 |
02:56 ET | 300 | 0.8668 |
02:58 ET | 400 | 0.8694 |
03:00 ET | 400 | 0.8648 |
03:05 ET | 2600 | 0.860194 |
03:12 ET | 100 | 0.8648 |
03:18 ET | 100 | 0.8602 |
03:23 ET | 13542 | 0.875 |
03:27 ET | 1871 | 0.8899 |
03:36 ET | 500 | 0.8888 |
03:43 ET | 100 | 0.8899 |
03:45 ET | 200 | 0.865 |
03:54 ET | 100 | 0.865 |
03:57 ET | 100 | 0.865 |
03:59 ET | 300 | 0.8648 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Equillium Inc | 30.6M | -3.6x | --- |
Microalliance Group Inc | 36.6M | 4.4x | --- |
Biofrontera Inc | 5.3M | -0.2x | --- |
Health-Chem Corp | 1.2K | 0.0x | --- |
CASI Pharmaceuticals Inc | 74.1M | -2.7x | --- |
Bon Natural Life Ltd | 7.3M | 0.7x | +78.05% |
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.6M |
---|---|
Revenue (TTM) | $42.6M |
Shares Outstanding | 35.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.83 |
EPS | $-0.24 |
Book Value | $0.64 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -22.79% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.